Thermo Fisher Scientific: Reinventing Its Growth Playbook With Precision Diagnostics and Pharma Services!

Thermo Fisher Scientific’s earnings call for the fourth quarter of 2025, presented by the company’s leadership, including CEO Marc Casper and CFO Stephen Williamson, provided a comprehensive overview of the fiscal performance across several areas. The call highlighted Thermo Fisher’s strong operational execution and strategic initiatives while noting some of the challenges faced and laying out expectations for 2026. For the fourth quarter of 2025, Thermo Fisher reported revenue growth of 7%, reaching $12.21 billion with an adjusted EPS growth of 8% to $6.57. The company’s annual performance saw revenue growth of 4% to $44.56 billion, with adjusted EPS increasing by 5% to $22.87. However, these results reflect a blended performance across business segments, with organic growth recorded at 3% for the quarter and 2% for the year. Exploration into the end market performances revealed diverse results.